1952 — Everest Medicines Income Statement
0.000.00%
- HK$6.17bn
- HK$4.20bn
- CNY125.93m
Annual income statement for Everest Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.054 | 12.8 | 126 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.031 | 8.15 | 91.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 176 | 688 | 1,026 | 270 | 1,059 |
Operating Profit | -176 | -688 | -1,026 | -257 | -933 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -215 | -5,658 | -1,009 | -247 | -844 |
Provision for Income Taxes | |||||
Net Income After Taxes | -215 | -5,658 | -1,009 | -247 | -844 |
Net Income Before Extraordinary Items | |||||
Net Income | -215 | -5,658 | -1,009 | -247 | -844 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -215 | -5,658 | -1,009 | -247 | -844 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.08 | -66.3 | -3.44 | -3.68 | -2.53 |